Cambridge Cognition wins £1.3 million contract as the cognitive assessment partner for a schizophrenia trial

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a £1.3 million contract as the cognitive assessment partner for a schizophrenia trial. Revenue from the contract is expected to be booked over the next three years. This is the fourth schizophrenia trial Cambridge Cognition has secured with this pharmaceutical client in seven months. The first three were announced by the Company on 1 September 2020 in a £2 million contract.

Cognitive impairment is a core feature of schizophrenia, with deficits frequently observed in memory, attention and executive functions. Impressed by the high degree of sensitivity CANTABTM cognitive assessments demonstrate in measuring these distinct processes and the quality of service the Company delivers, Cambridge Cognition has been named as the cognitive assessment provider for the fourth trial in the series.  

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“Schizophrenia affects more than 20 million people worldwide and we are pleased to be strengthening our relationship with a company that recognises the importance of sensitive and accurate cognitive assessment in developing effective therapeutics for the disorder. This quick succession of unusually large contracts with the same pharmaceutical company is a testament to the excellent customer experience and high-quality products Cambridge Cognition delivers.”  

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition – An excellent year for the company (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to discuss preliminary results for 2020. Matthew talks us through the highlights, explains how the company performed during the pandemic, where sales orders across the portfolio came from, progress

Cambridge Cognition Holdings

Cambridge Cognition Strong financial performance revenues up 34%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update and notice of results for the year ended 31 December 2020, together with details of a forthcoming change to

Cambridge Cognition Holdings

Cambridge Cognition wins new £750,000 digital health contract

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a new contract providing cognitive tests and electronic clinical outcome assessments for an Alzheimer’s trial. The total